G1 Therapeutics (NASDAQ:GTHX) Given New $3.00 Price Target at HC Wainwright

G1 Therapeutics (NASDAQ:GTHX) had its target price lowered by HC Wainwright from $9.00 to $3.00 in a research report report published on Tuesday, Benzinga reports. The firm currently has a buy rating on the stock.

A number of other equities research analysts have also recently weighed in on GTHX. Needham & Company LLC reaffirmed a buy rating and set a $12.00 price target on shares of G1 Therapeutics in a report on Thursday, June 13th. Wedbush reaffirmed an outperform rating and set a $3.00 price target (down from $5.00) on shares of G1 Therapeutics in a report on Monday.

G1 Therapeutics Price Performance

Shares of GTHX stock opened at $2.20 on Tuesday. G1 Therapeutics has a 12 month low of $1.08 and a 12 month high of $6.14. The company has a current ratio of 2.94, a quick ratio of 2.55 and a debt-to-equity ratio of 1.34. The stock has a 50 day moving average of $3.71 and a two-hundred day moving average of $3.59. The company has a market capitalization of $115.02 million, a P/E ratio of -3.55 and a beta of 1.71.

G1 Therapeutics (NASDAQ:GTHX) last issued its earnings results on Wednesday, May 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). G1 Therapeutics had a negative return on equity of 74.75% and a negative net margin of 36.40%. The company had revenue of $14.48 million during the quarter, compared to analyst estimates of $15.21 million. During the same period in the previous year, the company posted ($0.53) earnings per share. As a group, equities analysts expect that G1 Therapeutics will post -0.54 EPS for the current year.

Institutional Investors Weigh In On G1 Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in GTHX. Acadian Asset Management LLC acquired a new stake in shares of G1 Therapeutics in the 3rd quarter valued at $189,000. Algert Global LLC bought a new position in shares of G1 Therapeutics in the 3rd quarter worth $98,000. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of G1 Therapeutics by 68.3% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 204,200 shares of the company’s stock worth $294,000 after purchasing an additional 82,879 shares during the last quarter. Creative Financial Designs Inc. ADV boosted its position in shares of G1 Therapeutics by 98.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 35,280 shares of the company’s stock worth $108,000 after purchasing an additional 17,475 shares during the last quarter. Finally, abrdn plc bought a new position in shares of G1 Therapeutics in the 4th quarter worth $1,293,000. 24.21% of the stock is owned by institutional investors and hedge funds.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.